Stem definition | Drug id | CAS RN |
---|---|---|
4168 | 367514-87-2 |
Dose | Unit | Route |
---|---|---|
60 | mg | O |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 28, 2010 | FDA | SUNOVION PHARMS INC | |
March 25, 2020 | PMDA | Sumitomo Dainippon Pharma Co., Ltd. |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood prolactin abnormal | 851.95 | 21.72 | 168 | 9694 | 1953 | 53337251 |
Anosognosia | 828.55 | 21.72 | 165 | 9697 | 2024 | 53337180 |
Sexual dysfunction | 816.12 | 21.72 | 175 | 9687 | 3151 | 53336053 |
Disturbance in social behaviour | 763.76 | 21.72 | 161 | 9701 | 2660 | 53336544 |
Metabolic disorder | 720.48 | 21.72 | 173 | 9689 | 5254 | 53333950 |
Dystonia | 626.73 | 21.72 | 186 | 9676 | 12835 | 53326369 |
Personality change | 620.93 | 21.72 | 157 | 9705 | 5920 | 53333284 |
Sedation | 563.07 | 21.72 | 210 | 9652 | 29465 | 53309739 |
Dyskinesia | 541.53 | 21.72 | 208 | 9654 | 31625 | 53307579 |
Suicide attempt | 447.95 | 21.72 | 217 | 9645 | 57951 | 53281253 |
Schizophrenia | 388.41 | 21.72 | 122 | 9740 | 10157 | 53329047 |
Blood glucose increased | 278.90 | 21.72 | 175 | 9687 | 77186 | 53262018 |
Completed suicide | 224.26 | 21.72 | 193 | 9669 | 138008 | 53201196 |
Tardive dyskinesia | 208.87 | 21.72 | 72 | 9790 | 7998 | 53331206 |
Mania | 178.53 | 21.72 | 71 | 9791 | 11758 | 53327446 |
Insurance issue | 166.10 | 21.72 | 46 | 9816 | 2459 | 53336745 |
Akathisia | 163.45 | 21.72 | 61 | 9801 | 8510 | 53330694 |
Suicidal ideation | 117.63 | 21.72 | 94 | 9768 | 60417 | 53278787 |
Blood prolactin increased | 92.00 | 21.72 | 31 | 9831 | 3208 | 53335996 |
Psychotic disorder | 82.25 | 21.72 | 53 | 9809 | 24332 | 53314872 |
Delusion | 77.95 | 21.72 | 40 | 9822 | 11969 | 53327235 |
Condition aggravated | 76.53 | 21.72 | 169 | 9693 | 296965 | 53042239 |
Adverse drug reaction | 71.11 | 21.72 | 67 | 9795 | 53558 | 53285646 |
Persistent genital arousal disorder | 68.15 | 21.72 | 15 | 9847 | 304 | 53338900 |
Bipolar disorder | 62.96 | 21.72 | 30 | 9832 | 7656 | 53331548 |
Galactorrhoea | 60.31 | 21.72 | 24 | 9838 | 3971 | 53335233 |
Hallucination, auditory | 58.95 | 21.72 | 33 | 9829 | 11740 | 53327464 |
Confabulation | 51.74 | 21.72 | 12 | 9850 | 310 | 53338894 |
Depression | 51.46 | 21.72 | 108 | 9754 | 182944 | 53156260 |
Serotonin syndrome | 49.08 | 21.72 | 40 | 9822 | 26366 | 53312838 |
Restlessness | 46.92 | 21.72 | 40 | 9822 | 28047 | 53311157 |
Diarrhoea | 46.91 | 21.72 | 29 | 9833 | 625517 | 52713687 |
Weight increased | 44.46 | 21.72 | 109 | 9753 | 204458 | 53134746 |
Rheumatoid arthritis | 43.59 | 21.72 | 4 | 9858 | 314527 | 53024677 |
Off label use | 40.98 | 21.72 | 184 | 9678 | 472028 | 52867176 |
Drug ineffective | 39.78 | 21.72 | 272 | 9590 | 816973 | 52522231 |
Therapy cessation | 37.09 | 21.72 | 35 | 9827 | 27990 | 53311214 |
Arthralgia | 36.36 | 21.72 | 18 | 9844 | 439765 | 52899439 |
Extrapyramidal disorder | 34.68 | 21.72 | 24 | 9838 | 12378 | 53326826 |
Anxiety | 30.86 | 21.72 | 93 | 9769 | 196611 | 53142593 |
Agitation | 29.96 | 21.72 | 45 | 9817 | 58581 | 53280623 |
Oculogyric crisis | 29.86 | 21.72 | 11 | 9851 | 1477 | 53337727 |
Personality change due to a general medical condition | 29.28 | 21.72 | 6 | 9856 | 85 | 53339119 |
Depressed mood | 29.05 | 21.72 | 35 | 9827 | 36929 | 53302275 |
Parkinsonism | 28.93 | 21.72 | 19 | 9843 | 8994 | 53330210 |
Tremor | 28.34 | 21.72 | 68 | 9794 | 125668 | 53213536 |
Catatonia | 27.79 | 21.72 | 14 | 9848 | 4026 | 53335178 |
Joint swelling | 27.65 | 21.72 | 5 | 9857 | 234633 | 53104571 |
Hyperthermia | 27.35 | 21.72 | 18 | 9844 | 8551 | 53330653 |
Hyperprolactinaemia | 27.33 | 21.72 | 13 | 9849 | 3302 | 53335902 |
Blood insulin increased | 26.54 | 21.72 | 6 | 9856 | 138 | 53339066 |
Mental disorder | 25.87 | 21.72 | 27 | 9835 | 24349 | 53314855 |
Hallucination | 25.64 | 21.72 | 40 | 9822 | 53798 | 53285406 |
Anaemia | 24.92 | 21.72 | 10 | 9852 | 276708 | 53062496 |
Crying | 24.24 | 21.72 | 25 | 9837 | 22237 | 53316967 |
Metamyelocyte count increased | 23.95 | 21.72 | 6 | 9856 | 216 | 53338988 |
Apnoea | 23.86 | 21.72 | 16 | 9846 | 7837 | 53331367 |
Amenorrhoea | 23.60 | 21.72 | 17 | 9845 | 9332 | 53329872 |
Anger | 23.50 | 21.72 | 19 | 9843 | 12371 | 53326833 |
Urinary tract infection | 22.71 | 21.72 | 8 | 9854 | 239895 | 53099309 |
Change in seizure presentation | 22.68 | 21.72 | 6 | 9856 | 269 | 53338935 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Anosognosia | 321.81 | 28.67 | 61 | 4546 | 756 | 32508163 |
Blood prolactin abnormal | 292.28 | 28.67 | 57 | 4550 | 828 | 32508091 |
Disturbance in social behaviour | 256.36 | 28.67 | 57 | 4550 | 1608 | 32507311 |
Metabolic disorder | 212.04 | 28.67 | 58 | 4549 | 3895 | 32505024 |
Dystonia | 208.52 | 28.67 | 72 | 4535 | 10551 | 32498368 |
Sexual dysfunction | 202.33 | 28.67 | 62 | 4545 | 6227 | 32502692 |
Schizophrenia | 197.24 | 28.67 | 68 | 4539 | 9916 | 32499003 |
Dyskinesia | 159.05 | 28.67 | 74 | 4533 | 23529 | 32485390 |
Sedation | 149.88 | 28.67 | 66 | 4541 | 18460 | 32490459 |
Personality change | 146.37 | 28.67 | 46 | 4561 | 5013 | 32503906 |
Akathisia | 105.21 | 28.67 | 39 | 4568 | 6986 | 32501933 |
Suicide attempt | 92.44 | 28.67 | 61 | 4546 | 38183 | 32470736 |
Psychotic disorder | 84.55 | 28.67 | 48 | 4559 | 22972 | 32485947 |
Mania | 83.31 | 28.67 | 36 | 4571 | 9596 | 32499323 |
Completed suicide | 74.68 | 28.67 | 78 | 4529 | 92439 | 32416480 |
Blood glucose increased | 73.33 | 28.67 | 66 | 4541 | 65175 | 32443744 |
Tardive dyskinesia | 72.99 | 28.67 | 28 | 4579 | 5503 | 32503416 |
Suicidal ideation | 71.44 | 28.67 | 52 | 4555 | 38031 | 32470888 |
Hallucination, auditory | 68.22 | 28.67 | 32 | 4575 | 10318 | 32498601 |
Drug ineffective | 54.59 | 28.67 | 147 | 4460 | 383330 | 32125589 |
Extrapyramidal disorder | 52.45 | 28.67 | 28 | 4579 | 11867 | 32497052 |
Off label use | 52.44 | 28.67 | 126 | 4481 | 306194 | 32202725 |
Neuroleptic malignant syndrome | 52.43 | 28.67 | 32 | 4575 | 17463 | 32491456 |
Aggression | 42.53 | 28.67 | 39 | 4568 | 39350 | 32469569 |
Weight increased | 41.46 | 28.67 | 55 | 4552 | 83608 | 32425311 |
Paranoia | 38.22 | 28.67 | 22 | 4585 | 10777 | 32498142 |
Agitation | 36.97 | 28.67 | 43 | 4564 | 57193 | 32451726 |
Delusion | 36.78 | 28.67 | 23 | 4584 | 13085 | 32495834 |
Grandiosity | 33.12 | 28.67 | 8 | 4599 | 325 | 32508594 |
Insurance issue | 32.31 | 28.67 | 10 | 4597 | 1032 | 32507887 |
Restlessness | 29.53 | 28.67 | 26 | 4581 | 24855 | 32484064 |
Tremor | 29.35 | 28.67 | 46 | 4561 | 81231 | 32427688 |
Source | Code | Description |
---|---|---|
ATC | N05AE05 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Indole derivatives |
FDA EPC | N0000175430 | Atypical Antipsychotic |
MeSH PA | D018663 | Adrenergic Agents |
MeSH PA | D058669 | Adrenergic alpha-2 Receptor Antagonists |
MeSH PA | D000317 | Adrenergic alpha-Antagonists |
MeSH PA | D018674 | Adrenergic Antagonists |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D065127 | Dopamine D2 Receptor Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D058830 | Serotonin 5-HT2 Receptor Antagonists |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D012702 | Serotonin Antagonists |
MeSH PA | D014149 | Tranquilizing Agents |
CHEBI has role | CHEBI:37887 | adrenergic receptor blockaders |
CHEBI has role | CHEBI:48279 | 5-hydroxytryptamine antagonists |
CHEBI has role | CHEBI:48561 | dopamine blocker |
CHEBI has role | CHEBI:65191 | atypical antipsychotics |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Schizophrenia | indication | 58214004 | DOID:5419 |
Bipolar affective disorder, current episode depression | indication | 191627008 | DOID:3312 |
Suicidal thoughts | contraindication | 6471006 | |
Weight gain finding | contraindication | 8943002 | |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Lowered convulsive threshold | contraindication | 19260006 | |
Orthostatic hypotension | contraindication | 28651003 | |
Dysphagia | contraindication | 40739000 | |
Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
Hepatic failure | contraindication | 59927004 | |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Tardive dyskinesia | contraindication | 102449007 | |
Seizure disorder | contraindication | 128613002 | |
Impaired renal function disorder | contraindication | 197663003 | |
Cerebrovascular accident | contraindication | 230690007 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hyperprolactinemia | contraindication | 237662005 | DOID:12700 |
Transient ischemic attack | contraindication | 266257000 | DOID:224 |
Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
Syncope | contraindication | 271594007 | |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Senile dementia with psychosis | contraindication | 371026009 | |
Cardiovascular event risk | contraindication | 395112001 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.38 | Basic |
pKa2 | 0.27 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9174975 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9815827 | Feb. 20, 2024 | TREATMENT OF SCHIZOPHRENIA |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9555027 | May 26, 2026 | TREATMENT OF SCHIZOPHRENIA |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
120MG | LATUDA | SUNOVION PHARMS INC | N200603 | April 26, 2012 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
20MG | LATUDA | SUNOVION PHARMS INC | N200603 | Dec. 7, 2011 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
40MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
60MG | LATUDA | SUNOVION PHARMS INC | N200603 | July 12, 2013 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9259423 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER |
80MG | LATUDA | SUNOVION PHARMS INC | N200603 | Oct. 28, 2010 | RX | TABLET | ORAL | 9827242 | May 23, 2031 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 9.00 | DRUG LABEL | DRUG LABEL | |||
5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 9.33 | DRUG LABEL | DRUG LABEL | |||
5-hydroxytryptamine receptor 7 | GPCR | ANTAGONIST | Ki | 9.31 | DRUG LABEL | ||||
Alpha-2C adrenergic receptor | GPCR | Ki | 7.97 | DRUG LABEL | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 7.39 | DRUG LABEL | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 8.20 | DRUG LABEL | |||||
5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 8.17 | IUPHAR | ||||
5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.69 | IUPHAR | ||||
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.77 | IUPHAR |
ID | Source |
---|---|
D04820 | KEGG_DRUG |
367514-88-3 | SECONDARY_CAS_RN |
4030294 | VANDF |
4030301 | VANDF |
CHEBI:70735 | CHEBI |
CHEMBL1237021 | ChEMBL_ID |
CHEMBL1615372 | ChEMBL_ID |
7461 | IUPHAR_LIGAND_ID |
8247 | INN_ID |
DB08815 | DRUGBANK_ID |
22IC88528T | UNII |
213046 | PUBCHEM_CID |
1040027 | RXNORM |
177747 | MMSL |
27589 | MMSL |
d07705 | MMSL |
013606 | NDDF |
013607 | NDDF |
703115008 | SNOMEDCT_US |
703116009 | SNOMEDCT_US |
715585000 | SNOMEDCT_US |
D000069056 | MESH_DESCRIPTOR_UI |
C2003424 | UMLSCUI |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-464 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 24 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-465 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 24 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-466 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 24 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 13668-467 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 24 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-494 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-495 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-496 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-497 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 46708-498 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-494 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-495 | TABLET, FILM COATED | 40 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-496 | TABLET, FILM COATED | 60 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-497 | TABLET, FILM COATED | 80 mg | ORAL | ANDA | 31 sections |
Lurasidone Hydrochloride | Human Prescription Drug Label | 1 | 62332-498 | TABLET, FILM COATED | 120 mg | ORAL | ANDA | 31 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-302 | TABLET, FILM COATED | 20 mg | ORAL | NDA | 32 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-304 | TABLET, FILM COATED | 40 mg | ORAL | NDA | 32 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-306 | TABLET, FILM COATED | 60 mg | ORAL | NDA | 32 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-308 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 32 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63402-312 | TABLET, FILM COATED | 120 mg | ORAL | NDA | 32 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-082 | TABLET, COATED | 60 mg | ORAL | ANDA | 29 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-879 | TABLET, COATED | 20 mg | ORAL | ANDA | 29 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-880 | TABLET, COATED | 40 mg | ORAL | ANDA | 29 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-881 | TABLET, COATED | 80 mg | ORAL | ANDA | 29 sections |
Lurasidone Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65162-882 | TABLET, COATED | 120 mg | ORAL | ANDA | 29 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1812 | TABLET, FILM COATED | 60 mg | ORAL | NDA | 31 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1936 | TABLET, FILM COATED | 120 mg | ORAL | NDA | 31 sections |
Latuda | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-3010 | TABLET, FILM COATED | 80 mg | ORAL | NDA | 31 sections |